KATHLEEN ENNIS: Open Payments
NPI 1750417358 · COS COB, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,148 in 90 payments from 11 companies in 2025. Trend: 2023 $3,565 · 2024 $2,570 · 2025 $3,148
Food & beverage: $3,148
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $797 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $701 |
| Otsuka America Pharmaceutical, Inc. | 14 | $572 |
| Alkermes, Inc. | 8 | $239 |
| E.R. Squibb & Sons, L.L.C. | 14 | $239 |
| Lundbeck LLC | 8 | $219 |
| Teva Pharmaceuticals USA, Inc. | 2 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Janssen Pharmaceuticals, Inc | 1 | $84 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
Products named: VRAYLAR, CAPLYTA, REXULTI, COBENFY, ABILIFY ASIMTUFII, ENTYVIO, ABILIFY MAINTENA, LYBALVI.
Industry payments across CT — which companies pay providers there.
